Event Type
Disclosure
Voluntary
Variant
8-K
of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Sect
Other Events. On December 18, 2025, the Company issued a press release announcing positive results in the Phase 1 pharmacokinetic trial of a combination of its
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Document 99.1 Investor Presentation of Sagimet Biosciences Inc., dated December 18, 2025 99.2 Press